Literature DB >> 29393514

Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Aditi Shendre1, Gaurav M Parmar2, Chrisly Dillon3, Timothy Mark Beasley4, Nita A Limdi3.   

Abstract

OBJECTIVE: We assessed the influence of age on warfarin dose, percentage time in target range (PTTR), and risk of major hemorrhage.
DESIGN: Warfarin users recruited into a large prospective inception cohort study were categorized into three age groups: young (younger than 50 yrs), middle aged (50-70 yrs), and elderly (older than 70 yrs). The influence of age on warfarin dose and PTTR was assessed using regression analysis; risk of major hemorrhage was assessed using proportional hazards analysis. Models were adjusted for demographic, clinical, and genetic factors.
SETTING: Two outpatient anticoagulation clinics. PARTICIPANTS: A total of 1498 anticoagulated patients. OUTCOMES: Warfarin dose (mg/day), PTTR, major hemorrhage.
RESULTS: Of the 1498 patients, 22.8% were young, 44.1% were middle aged, and 33.1% were elderly. After accounting for clinical and genetic factors, compared with young warfarin users, warfarin dose requirements were 10.6% lower among the middle aged and an additional 10.6% lower for the elderly. Compared with young patients, middle-aged and elderly patients spent more time in target international normalized ratio (INR) range (p<0.0001), despite having fewer INR assessments (p<0.0001). Compared with young warfarin users, absolute risk of hemorrhage was marginally higher among the middle aged (p=0.08) and significantly higher among the elderly (p=0.016). Compared with young warfarin users, after adjustment, the relative risk of hemorrhage increased by 31% for each age category (p=0.026).
CONCLUSIONS: In a real-world setting, despite achieving better anticoagulation control, elderly patients had a higher risk of major hemorrhagic events. As the population ages and the candidacy for oral anticoagulation increases, strategies that mitigate the elevated risk of hemorrhage need to be identified.
© 2018 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  age; major hemorrhage; percentage time in target range (PTTR); warfarin dose

Mesh:

Substances:

Year:  2018        PMID: 29393514      PMCID: PMC6014885          DOI: 10.1002/phar.2089

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  54 in total

1.  Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry.

Authors:  Jonathan C Hsu; Thomas M Maddox; Kevin F Kennedy; David F Katz; Lucas N Marzec; Steven A Lubitz; Anil K Gehi; Mintu P Turakhia; Gregory M Marcus
Journal:  JAMA Cardiol       Date:  2016-04-01       Impact factor: 14.676

2.  Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.

Authors:  Keitaro Senoo; Marco Proietti; Deirdre A Lane; Gregory Y H Lip
Journal:  Am J Med       Date:  2015-10-22       Impact factor: 4.965

3.  Aging and the anticoagulant response to warfarin therapy.

Authors:  J H Gurwitz; J Avorn; D Ross-Degnan; I Choodnovskiy; J Ansell
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

4.  US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014.

Authors:  Nadine Shehab; Maribeth C Lovegrove; Andrew I Geller; Kathleen O Rose; Nina J Weidle; Daniel S Budnitz
Journal:  JAMA       Date:  2016-11-22       Impact factor: 56.272

5.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

6.  The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: a pilot study.

Authors:  Tu Ngoc Nguyen; Marie-Christine Morel-Kopp; Dominic Pepperell; Robert Graham Cumming; Sarah Nicole Hilmer; Christopher Morice Ward
Journal:  Aging Clin Exp Res       Date:  2017-03-02       Impact factor: 3.636

7.  Varying degrees of Apis mellifera ligustica introgression in protected populations of the black honeybee, Apis mellifera mellifera, in northwest Europe.

Authors:  Annette B Jensen; Kellie A Palmer; Jacobus J Boomsma; Bo V Pedersen
Journal:  Mol Ecol       Date:  2005-01       Impact factor: 6.185

8.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

Review 9.  A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks.

Authors:  Beata Bajorek
Journal:  Ther Adv Drug Saf       Date:  2011-04

10.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

View more
  9 in total

Review 1.  Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Authors:  Aditi Shendre; Chrisly Dillon; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2018-10-22       Impact factor: 2.533

Review 2.  Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review.

Authors:  Amr Mohamed Fahmi; Hazem Elewa; Islam El Jilany
Journal:  Int J Clin Pharm       Date:  2022-03-05

Review 3.  Molecular and Clinical Issues about the Risk of Venous Thromboembolism in Older Patients: A Focus on Parkinson's Disease and Parkinsonism.

Authors:  Claudio Tana; Fulvio Lauretani; Andrea Ticinesi; Beatrice Prati; Antonio Nouvenne; Tiziana Meschi
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

4.  VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People.

Authors:  Lindsay M Henderson; Renee F Robinson; Lily Ray; Burhan A Khan; Tianran Li; Denise A Dillard; Brian D Schilling; Mike Mosley; Patricia L Janssen; Alison E Fohner; Allan E Rettie; Kenneth E Thummel; Timothy A Thornton; David L Veenstra
Journal:  Clin Transl Sci       Date:  2019-03-01       Impact factor: 4.689

Review 5.  Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions.

Authors:  Natalia A Shnayder; Marina M Petrova; Pavel A Shesternya; Alina V Savinova; Elena N Bochanova; Olga V Zimnitskaya; Elena A Pozhilenkova; Regina F Nasyrova
Journal:  Biomedicines       Date:  2021-04-22

6.  Pharmacists' interventions improve health-related quality of life of rural older person on warfarin: a randomized controlled trial.

Authors:  Slaven Falamić; Marko Lucijanić; Maja Ortner-Hadžiabdić; Srećko Marušić; Vesna Bačić-Vrca
Journal:  Sci Rep       Date:  2021-11-09       Impact factor: 4.379

7.  Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.

Authors:  Zeina N Al-Mahayri; Lubna Q Khasawneh; Mais N Alqasrawi; Sahar M Altoum; Gohar Jamil; Sally Badawi; Dana Hamza; Lizy George; Anwar AlZaabi; Husam Ouda; Fatma Al-Maskari; Juma AlKaabi; George P Patrinos; Bassam R Ali
Journal:  Hum Genomics       Date:  2022-09-25       Impact factor: 6.481

8.  Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.

Authors:  Arinao Ndadza; Sarudzai Muyambo; Pindile Mntla; Ambroise Wonkam; Emile Chimusa; Andre P Kengne; Mpiko Ntsekhe; Collet Dandara
Journal:  J Thromb Haemost       Date:  2021-09-29       Impact factor: 16.036

9.  Nonalcoholic fatty liver disease impacts the control of the international normalized ratio in patients with atrial fibrillation.

Authors:  Xi Zhang; Guang-Yu Chen; Zhao-Xia Wang; Xue-Hai Li; Rong Luo; Yi-Gang Li; Fan Yang; Xin Zhou; Feng Jiang; Yao-Sheng Wang
Journal:  Ann Transl Med       Date:  2020-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.